Emergency reversal of antithrombotic treatment
- 12 November 2008
- journal article
- review article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 4 (2), 137-145
- https://doi.org/10.1007/s11739-008-0201-8
Abstract
The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In case of serious or even life-threatening bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, anticoagulant treatment can be reversed by various specific strategies. Heparin and heparin derivatives can be counteracted by protamine sulphate, whereas the anticoagulant effect of vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates. The anti-hemostatic effect of aspirin and other anti-platelet strategies can be corrected by the administration of platelet concentrate or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors has been introduced and most of these agents are presently being evaluated in clinical studies. The new generation anticoagulants include specific inhibitors of factor IIa, factor Xa (including pentasaccharides) and agents that interfere with tissue factor activity. A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although in some cases the administration of recombinant factor VIIa may be an option.Keywords
This publication has 83 references indexed in Scilit:
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood, 2008
- Invasive procedures in the outpatient setting: Managing the short-acting acenocoumarol and the long-acting phenprocoumonThrombosis and Haemostasis, 2007
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- New antithrombotics in the treatment of thromboembolic diseaseEuropean Journal of Internal Medicine, 2005
- Coronary syndromes following aspirin withdrawalJournal of the American College of Cardiology, 2005
- Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteersThrombosis and Haemostasis, 2004
- Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulationThe American Journal of Cardiology, 1999
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Partial Reversal of Low Molecular Weight Heparin (PK 10169) Anti-Xa Activity by Protamine Sulfate: In vitro and in vivo Study during Cardiac Surgery with Extracorporeal CirculationPathophysiology of Haemostasis and Thrombosis, 1986